InPACT
An international study looking at the treatment of inguinal lymph glands in cancer of the penis
Trial Summary:
This study will determine the optimum sequencing of surgery, chemotherapy and chemo-radiotherapy in the management of locally advanced cancer of the penis, and attempt to define the relative benefits of these approaches in routine clinical practice. The proposed study will address the value, toxicity and deliverability of neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy in patients with inguinal lymph node metastases. Additionally, this trial will address the question of whether there is any added benefit for prophylactic pelvic lymph node dissection (PLND) plus adjuvant chemoradiotherapy over adjuvant chemoradiotherapy alone.
RT QA Summary:
All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.
| QA Process | QA Activity | Required for Trial | Additional Details |
|---|---|---|---|
| Pre-Accrual | Facility Questionnaire |  | |
| Outlining Benchmark Case | | 2 cases | |
| Planning Benchmark Case | | 1 case | |
| During Accrual | Individual Case Review | | Prospective: first 3 patients Retrospective: all patients |
| Data collection | | All patients | |
| Dosimetry Audit | Evidence of recent external dosimetry audit | |
RTTQA Contact: inpact.rttqa@wales.nhs.uk
Chief Investigator: Dr. Steve Nicholson
RT Leads: Dr. Jim Barber (Velindre Cancer Centre), Dr. Alison Tree (University College Hospital), Dr. Anita Mitra (Royal Marsden Hospital)
Sponsor: Institute of Cancer Research, inpact-icrctsu@icr.ac.uk
Funder: Cancer Research UK – Stand Up to Cancer